Results 201 to 210 of about 101,624 (260)

Correction to: Pharmacokinetics and pharmacodynamics of desoxycorticosterone pivalate in dogs with hypoadrenocorticism. [PDF]

J Vet Intern Med
europepmc   +1 more source

Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics. [PDF]

Res Pract Thromb Haemost
You CW, Baek HJ, Park YS, Kim BR, Lee H, Kim SH, Hwang SH, Choi EJ.   +7 more
europepmc   +1 more source

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model‐based simulation of the positioning imatinib for pulmonary arterial hypertension trial

British Journal of Clinical Pharmacology, EarlyView.
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said, Robert B. de Mooij, Dian Jiao, Reitze J. Ovelgonne, Rami Biram, Juan Delgado‐SanMartin, Alexander M. K. Rothman, Sofia S. Villar, Andreas A. Roussakis, Jurjan Aman, Ron A. A. Mathôt, Eleonora L. Swart, Martin R. Wilkins, Imke H. Bartelink   +13 more
wiley   +1 more source

Impact of Obesity on Propofol Dosing: Implications for Anesthetic Outcomes. [PDF]

Cureus
Sawires J, Chowdhury S, Girardin CR, Vega G, Weissman B, Soti V.   +5 more
europepmc   +1 more source

Dose‐related propofol resistance in COVID‐19 patients: Altered drug plasma levels, mechanistic insights from neuronal‐derived extracellular vesicles and miRNA analysis

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Critical care for COVID‐19 patients presents unique challenges, particularly in sedation management. Patients demonstrate notable dose‐related resistance to propofol, potentially due to complex pharmacokinetic alterations. Emerging evidence suggests that plasma extracellular vesicle‐associated miRNA represents valuable predictive ...
Debora Curci, Carlotta Bidoli, Marco Gerdol, Charisse Winston, Robert A. Rissman, Giuliana Decorti, Antonella Fabretto, Andrea Taddio, Gabriele Stocco, Erik Roman‐Pognuz, Marianna Lucafò   +10 more
wiley   +1 more source

<i>In vitro</i> pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against <i>Mycobacterium tuberculosis</i>. [PDF]

Front Microbiol
Aguilar-Ayala DA, Rabodoarivelo MS, Eveque-Mourroux MR, Leding AAM, Sonnenkalb L, Picó Marco A, Willand N, Serbina N, Simonsson USH, Lucía A, Ramón-García S.   +10 more
europepmc   +1 more source

Patient‐reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme

British Journal of Clinical Pharmacology, EarlyView.
Aim Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error‐prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological/pharmaceutical care programme for children and their caregivers during OAT treatment ...
Phyllis Lensker, Lisa Cuba, Frank Dörje, Martin F. Fromm, Markus Metzler   +4 more
wiley   +1 more source

In Response. [PDF]

Anesth Analg
Beukers AM, Hollmann MW, Eberl S, Hermanns H.   +3 more
europepmc   +1 more source

Acute toxic leucoencephalopathy following protonitazene ingestion

British Journal of Clinical Pharmacology, EarlyView.
Background Distribution of illicit counterfeit alprazolam containing the highly potent synthetic opioid‐receptor agonist protonitazene recently resulted in a number of severe overdoses in Ireland. We report three cases that presented to our hospital, within 6 weeks of one another, following ingestion of illicitly‐sourced alprazolam.
Ruadhan O'Laoi, Holly Acton, Pierce Kavanagh, Isabelle Hunt, Niall Sheehy, Cormac Kennedy   +5 more
wiley   +1 more source

Translational development of crisugabalin for neuropathic pain

British Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João, Jilly Octoria Tagore Chan, Luísa Mendes Araújo, André Batista João, Raquel Mattos Filgueiras, Paulo César Ragazzo   +5 more
wiley   +1 more source